Marshall Wace North America’s Nektar Therapeutics NKTR Stock Holding History

Marshall Wace North America’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-2,248	Closed	-$579K	–	1617
2021 Q2	$579K	Buy	+2,248	New	+$622K	﹤0.01%	1136
2019 Q2	–	Sell	-3,949	Closed	-$1.99M	–	1456
2019 Q1	$1.99M	Sell	3,949 -3,161	-44%	-$1.87M	0.01%	513
2018 Q4	$3.51M	Buy	+7,110	New	+$4.29M	0.03%	320
2018 Q2	–	Sell	-25,181	Closed	-$40.1M	–	1587
2018 Q1	$40.1M	Buy	25,181 +19,769	+365%	+$25.5M	0.2%	119
2017 Q4	$4.85M	Buy	+5,412	New	+$3.2M	0.03%	588
2017 Q3	–	Sell	-14,170	Closed	-$4.25M	–	1431
2017 Q2	$4.25M	Sell	14,170 -54,178	-79%	-$15.7M	0.03%	543
2017 Q1	$23.6M	Buy	+68,348	New	+$15.4M	0.19%	149

Other funds holding NKTR

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Marshall Wace North America's NKTR Position: Q3 2021 in Review

Marshall Wace North America sold out of Nektar Therapeutics (NKTR) in Q3 2021, closing a stake of 2,248 shares — an estimated $579K sold.

Marshall Wace North America first reported a position in NKTR in Q1 2017 and held it in 7 quarters. The position peaked at $40.1M in Q1 2018. 241 funds tracked by Wall St. Rank hold NKTR as of Q3 2021.

Marshall Wace North America reported no remaining Nektar Therapeutics position as of Q3 2021 after selling out during the quarter.
Marshall Wace North America sold 2,248 Nektar Therapeutics shares in Q3 2021, an estimated $579K.
Marshall Wace North America first reported a position in Nektar Therapeutics in Q1 2017 and held it in 7 quarters.
Marshall Wace North America's Nektar Therapeutics position peaked at $40.1M in Q1 2018.
241 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2021.

Based on Marshall Wace North America's 13F filing for Q3 2021, filed 15 Nov 2021.